Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04377165
Other study ID # Care Collective Study
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date May 6, 2020
Est. completion date August 26, 2020

Study information

Verified date April 2020
Source The University of Queensland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This project is a randomised trial in order to determine if "gamification" can result in behaviour change for healthcare workers in the residential aged care setting. The app is for Age Care and care workers at the front line who are working to protect those most vulnerable to COVID-19. There are 2 groups in this trial on group will receive current and accurate information from an app. The other group will receives the app with the addition of a gamification competent, this will include rewarding experiences for staff doing safety behaviours and wellbeing behaviours. The purpose of the gamification is to create a calming and reassuring experience that injects positivity and joy where possible during this stressful time.


Description:

The study design will be a multi- centre cluster randomised control trial, where Age Care facilities are randomised into two groups: 1. Newsfeed- gets the app with newsfeed only 2. Gamification group- gets the full gamified app, including the newsfeed Workers in our network of residential aged care facilities will be invited to participate in a study of communication of information regarding COVID-19 and how they will play a role in preventing its spread.


Recruitment information / eligibility

Status Terminated
Enrollment 34
Est. completion date August 26, 2020
Est. primary completion date August 26, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - Age Health Care Worker Exclusion Criteria: -

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Gamification
This will provide the user with the newsfeed function and the addition of a gamification function
Newsfeed function
This will provide the user with reliable accurate information on the pandemic.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
The University of Queensland

Outcome

Type Measure Description Time frame Safety issue
Primary To compare the hours of sick leave used over the course of the 4-week period post randomisation for each group Compare the number of sick leave prior to users utilising the app and at the end of the 4 weeks between the arms 4 weeks
Secondary To compare handwashing behaviour Compare the amount of soap/sanitiser used between the arms 4 weeks
Secondary To compare self-testing rates Compare the number of self tests between the two arms 4 weeks
Secondary To compare the level of surface wipe down Compare the amount of wipes/disinfectant used between the two arms 4 weeks
Secondary To compare number of COVID-19 tests completed in Facilities Compare the number of COVID-19 tests between the two arms 4 weeks
Secondary To compare the number of COVID 19 infections in facilities Compare the number of COVID-19 infections between the arms 4 weeks
Secondary To compare the other types of outbreaks (Flu, gastroenteritis) Compare the number of flu and gastroenteritis outbreaks between the arms 4 weeks
Secondary To compare the awareness of COVID 19 training available to workers in the facilities Compare the COVID 19 training between the two arms, this is via a self reported survey 4 weeks
Secondary To compare the awareness of PPE training available to workers in the facilities Compare the awareness of PPE training of the workers in the two arms, this is captured in self reported survey 4 weeks
Secondary To compare the levels of PPE material used in Compare the amount of PPE used between the arms 4 weeks
Secondary To compare the wellbeing and self-efficacy of the two groups Compare the wellbeing and self-efficacy between the two arms, this is captured in a self reported survey. 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT05523089 - The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults Phase 2
Completed NCT05009251 - Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake N/A
Completed NCT03282240 - Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US Phase 3
Completed NCT00971425 - Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1) Phase 3
Completed NCT00968526 - Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT00968539 - Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT05525494 - Patient Portal Flu Vaccine Reminders (5) N/A
Completed NCT04074928 - Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects Phase 3
Completed NCT04695717 - This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam Phase 3
Completed NCT05012163 - Lottery Incentive Nudges to Increase Influenza Vaccinations N/A
Completed NCT03888989 - Response to Influenza Vaccine During Pregnancy Phase 1
Completed NCT04109222 - Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively Phase 4
Completed NCT02587221 - Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age Phase 3
Completed NCT03453801 - The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Phase 1
Completed NCT01440387 - A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older Phase 3
Terminated NCT01195779 - Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children Phase 2
Completed NCT03321968 - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Phase 3
Completed NCT00972517 - Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children Phase 3
Completed NCT04570904 - Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
Recruiting NCT03331991 - Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel N/A